SSTR2 and cancer: The same results were observed in the inflammatory pathway and T cytotoxic pathway, suggesting that SSTR2-high groups showed a stronger inflammatory and cytotoxic immune environment than SSTR2-low groups in most cancers (inflammatory pathway: 100%; T cytotoxic pathway: 92.31%, Figures 2L,M).